Form 6-K BioLineRx Ltd. For: Nov 22

Go back to Form 6-K BioLineRx Ltd. For: Nov 22

Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q3 Results

November 22, 2016 2:39 PM UTC

Roth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target following Q3 results reported on Tuesday.

The analyst commented, We are encouraged by the multiple collaborations initiated between BLRX and biopharma in both clinical and preclinical staged projects, spanning multiple indications.

We believe that BL-8040 remains the lead value driver for BLRX with 1) partial results for the Phase II study of... More

BioLineRx (BLRX) Tops Q3 EPS by 4c

November 22, 2016 8:07 AM UTC

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07).

The Company held $38.9 million in cash, cash equivalents and short-term bank deposits as of September 30, 2016.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

... More